MS6105
MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity[1]. MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Product Specifications
CAS Number
2891709-58-1
UNSPSC
12352005
Target
PROTACs
Type
Reference compound
Related Pathways
PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ms6105.html
Purity
99.2
Solubility
10 mM in DMSO
Smiles
CC1=C(SC=N1)C2=CC=C(C=C2)CNC([C@@H]3C[C@H](CN3C([C@H](C(C)(C)C)NC(CCCCCCCCCCCC(NCCCCC#CC4=CC=CC(C5=NN(C(CC6CC6)=C5CC7=CC=C(C=C7)S(N)(=O)=O)C8=NC(C(O)=O)=CS8)=C4)=O)=O)=O)O)=O
Molecular Formula
C65H81N9O9S3
Molecular Weight
1228.59
References & Citations
[1]Ning Sun, et al. Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. J Med Chem. 2023 Jan 12;66 (1) :596-610.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E-AB-V1029-01 100 µL
SARS-CoV-2 Spike RBD (Bebtelovimab biosimilar) Neutralizing Antibody
Sign In for Pricing
View Details E-AB-V1029-02 200 µL
SARS-CoV-2 Spike RBD (Bebtelovimab biosimilar) Neutralizing Antibody
Sign In for Pricing
View Details 
